ProCE Banner Activity

Treating a Patient With Newly Diagnosed Metastatic EGFR Mutant–Positive NSCLC and High PD-L1 Expression

Multimedia
Leora Horn, MD, MSc, FRCPC, provides insight on the optimal treatment of patients with advanced NSCLC and both an oncogenic driver mutation and high PD-L1 tumor expression.

Released: May 29, 2018

Share

Faculty

Leora Horn

Leora Horn, MD, MSc

Assistant Professor, Hematology Oncology/Medicine
Vanderbilt Ingram Cancer Center
Vanderbilt University
Nashville, Tennessee

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AstraZeneca

Bristol Myers Squibb

Celgene TEXT Only

Genentech TEXT Only

Lilly

Merck Oncology

Novartis Pharmaceuticals Corporation

Takeda Oncology

Learning Objectives

  • Apply the available data, treatment guidelines, and expert recommendations to select therapy for NSCLC positive for sensitizing EGFR mutations, ALK or ROS1 gene rearrangements, or high PD-L1 expression

Faculty Disclosure

Primary Author

Leora Horn, MD, MSc

Assistant Professor, Hematology Oncology/Medicine
Vanderbilt Ingram Cancer Center
Vanderbilt University
Nashville, Tennessee

Leora Horn, MD, MSc, FRCPC, has disclosed that she has received consulting fees from AbbVie, AstraZeneca, Bristol-Myers Squibb, Genentech, Lilly, Merck, and Xcovery and funds for research support from Boehringer Ingelheim and Xcovery.

Staff Disclosure

Staff

Rachael M. Andrie, PhD

Clinical Editor

Rachael M. Andrie, PhD, has no real or apparent conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no real or apparent conflicts of interest to report.